Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2021 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces First Quarter 2021 Results and Update

Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer Advancing BRILLIANCE trial of EDIT-101 for LCA10; clinical data expected by year-end RUBY trial of...
May 05, 2021 06:59 ET | Source: Editas Medicine, Inc.

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s...
May 04, 2021 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the Treatment of Genetic Ocular Diseases at the American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced three presentations, including one from a research...
May 01, 2021 07:11 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treatment of Genetic Ocular Diseases at the Association for Research in Vision and Ophthalmology Annual Meeting

CAMBRIDGE, Mass., May 01, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that two scientific abstracts have been accepted for...
April 28, 2021 07:01 ET | Source: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing First Quarter 2021 Results and Corporate Update

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...
February 25, 2021 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Fourth Quarter and Full Year 2020 Results and Update

Strengthened Leadership by Appointing James (Jim) C. Mullen as President and Chief Executive Officer, and Lisa A. Michaels, M.D., as Chief Medical Officer Appointed Meeta Chatterjee, Ph.D., to Board...
February 18, 2021 16:02 ET | Source: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...
February 08, 2021 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer

CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy)...
January 20, 2021 22:30 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Pricing of Offering of Common Stock

CAMBRIDGE, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced the pricing of an underwritten offering of 3,500,000 shares...
January 19, 2021 16:01 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Offering of Common Stock

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and sell 3,500,000 shares of its...